ResearcherSichuan UniversityActive in the last 2 years

Peipei Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7580-9627; OpenAlex author ID A5022086231. Sources: OpenAlex.

Their work

Papers: 2
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 5

Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: none · 2023: none · 2024: 1 paper

Papers 2

The ‌BCL2-associated athanogene-3-Interferon-induced transmembrane protein 2 axis enhances pancreatic ductal adenocarcinoma growth via the Mitogen-activated pr… Co-author DOI 10.1093/carcin/bgae053 ↗
Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer. Co-author DOI 10.1002/jcp.28981 ↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Tongbo Zhu · 2 shared papers, 2020–2024 · strength 0.35
- Paper The ‌BCL2-associated athanogene-3-Interferon-induced transmembrane protein 2 axis enhances pancreatic ductal adenocarci… DOI 10.1093/carcin/bgae053 ↗
- Paper Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer. DOI 10.1002/jcp.28981 ↗
Yu Zhang · 1 shared paper, 2024 · strength 0.24
- Paper The ‌BCL2-associated athanogene-3-Interferon-induced transmembrane protein 2 axis enhances pancreatic ductal adenocarci… DOI 10.1093/carcin/bgae053 ↗
Xia Wang · 1 shared paper, 2024 · strength 0.24
- Paper The ‌BCL2-associated athanogene-3-Interferon-induced transmembrane protein 2 axis enhances pancreatic ductal adenocarci… DOI 10.1093/carcin/bgae053 ↗
Hongmei Zhang · 1 shared paper, 2020 · strength 0.11
- Paper Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer. DOI 10.1002/jcp.28981 ↗
Changyan Chen · 1 shared paper, 2020 · strength 0.11
- Paper Mu-KRAS attenuates Hippo signaling pathway through PKCι to sustain the growth of pancreatic cancer. DOI 10.1002/jcp.28981 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.